A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

ClinicalTrials.gov ID: NCT01685268

Public ClinicalTrials.gov record NCT01685268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone

Study identification

NCT ID: NCT01685268
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Enrollment: 49 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

AT13387 Drug
Prednisone Drug
abiraterone acetate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2012
Primary completion: Jun 30, 2014
Completion: Nov 30, 2014
Last update posted: Aug 1, 2024

2012 – 2014

United States locations

U.S. sites: 20
U.S. states: 12
U.S. cities: 19

Facility	City	State	ZIP	Site status
University of California, Los Angeles Institute of Urologic Oncology	Los Angeles	California	90024	—
Stanford Cancer Center	Stanford	California	94305	—
Holy Cross Hospital	Fort Lauderdale	Florida	33308	—
Florida Cancer Specialists-Fort Myers	Fort Myers	Florida	33916	—
Lakeland Regional Cancer Center	Lakeland	Florida	33805	—
Southern Illinois University School of Medicine	Springfield	Illinois	62702	—
University of Maryland, Greenebaum Cancer Center	Baltimore	Maryland	21201	—
Center for Cancer & Blood Disorders	Bethesda	Maryland	20817	—
Washington University School of Medicine	St Louis	Missouri	63110	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada	89169	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Clinical Research Alliance, Inc.	Lake Success	New York	11042	—
Columbia University Medical Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
SUNY Upstate Medical University	Syracuse	New York	13210	—
Cleveland Clinic	Cleveland	Ohio	44195	—
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15232	—
The West Clinic	Memphis	Tennessee	38120	—
Northwest Medical Specialists, PLLC	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01685268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 1, 2024 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01685268 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →